TScan Therapeutics discovers and develops TCR‑T cell therapies targeting shared, clinically‑derived antigens using a proprietary high‑throughput platform that also assesses off‑target TCR interactions. The company is advancing both hematologic and solid tumor programs, with lead liquid tumor programs TSC‑100 and TSC‑101 expected to enter clinical development in 2021. TScan plans to progress its first two TCR‑T assets into the clinic in 2021 and advance three additional programs into the clinic in 2022. For solid tumors it is advancing a multi‑TCR program and intends to nominate an initial set of three target candidates in 2021 with IND submissions to follow in 2022. The company has a strategic discovery partnership with Novartis from 2020 and is exploring use of its target discovery technology for infectious and autoimmune diseases. Prior to this financing the company had raised over $180 million to date; proceeds from the announced round will be used to advance the pipeline into the clinic. TScan designs therapies that reprogram a patient's own T cells to recognize and fight cancer using naturally occurring T-cell receptors (TCRs). Its technology scans TCRs against target antigens in a genome-wide, high-throughput, and unbiased fashion. The company has discovered novel antigens from TCRs, novel TCRs from known antigens, and previously uncharacterized off-targets of known TCRs. TScan is developing a portfolio of TCR therapies for patients with both liquid and solid tumors. With completion of the Series B, TScan has raised approximately $60 million in funding and says it is well positioned to discover novel tumor-reactive TCR targets and to develop TCR–target pairs across indications. The company states these resources will support its oncology development efforts.

Total raised

$160M

Funding rounds

2

Latest round

Series C

Latest activity

Jan 2021